HIV ile enfekte olan obez bireylerde Sistatin- C

Abstract

Amaç: Sistatin-C böbrek fonksiyonlarını gösteren glomerüler filtrasyon hızını GFR belirlemede kullanılan bir parametre olup obezitede arttığı bilinmektedir. Bu çalışmada amacımız HIV ile enfekte olan obez bireylerde GFR hesaplamasında Sistatin-C’nin etkisini araştırmaktır.Yöntem: Enfeksiyon Hastalıkları HIV polikliniğine başvuran HIV ile enfekte hastalardan obez olanlar çalışmaya dahil edildi. Bireylerin düz bir zeminde çıplak ayakla ve sırtları duvara gelecek şekilde dururken boy uzunlukları ölçüldükten sonra bioimpedans cihazında Tip-BC-418-MAIII, Tanita Body Composition Analyzer; Tanita, Tokyo, Japan tüm vücut analizi yapılarak kilo, beden kütle indeksi BMI , yağ yüzdesi, yağ ağırlığı ve yağsız ağırlıkları tespit edildi. Biyokimyasal verilerine retrospektif olarak ulaşılarak değerlendirme yapıldı. Sistatin-C, kreatinin değerleri ölçülmüş olan hastaların CKD- EPİ GFR Chronic Kidney Disease Epidemiology Collaboration equation glomerular filtration rate , GFRcr kreatinin-GFR , GFRcys sistatin-GFR ve GFRcrcys kombine-GFR değerleri hesaplandı.Bulgular: Yağ yüzdesi fazlalığı %9.21’in üstünde olan HIV ile enfekte bireylerde n=5 , sistatin-C’nin; vücut ağırlığı ve total kolesterol ile orantılı olarak yüksek bir group of HIV infected and excess fat percentage over 9.21%. Cystatin-C decreased with GFRcys in the group of HIV infected and excess fat percentage under 9.21%.Conclusion: Higher correlation with cystatin-C and high body weight in HIV infected with excess fat percentage obese individuals suggests that inflammation due to HIV infection and excess fat mass together contribute to cystatin-C increasing levels. More studies are needed in large number of groups

Keywords

• HIV enfeksiyonu, GFR, obezite, yağ dokusu

Cystatin-C in HIV-infected obese individuals

Abstract

Objective: Cystatin-C is a parameter used to determine the glomerular filtration rate GFR which indicates renal function. It is also known that cystatin-C increases in obesity. The aim of this study was to investigate the effect of cystatin-C on GFR calculation in HIV-infected obese individuals.Methods: Female and male HIV-infected obese patients who applied to the Infectious Diseases outpatient clinic were included in the study. Their heights were measured while they were barefooted and back touching a wall. The weight, body mass index BMI , fat percentage, fat mass and fat free mass, were determined using Bio-impedance analyzer device Tip-BC-418-MAIII, Tanita Body Composition Analyzer; Tanita, Tokyo, Japan . Biochemical data of patients were evaluated retrospectively. CKD- EPI GFR Chronic Kidney Disease Epidemiology Collaboration equation glomerular filtration rate , GFRcr creatinin-GFR , GFRcys cystatin-GFR ve GFRcr-cys combined-GFR were calculated using creatinin and cystatin-C values.Results: Cystatin-C proportionally increased with a high correlation with body weight and total cholesterol, and decreased with GFRcr, GFRcys, GFRcr-cys in the en önemli sağlık sorunlarından biri haline gelmiş Dünyada olduğu gibi ülkemizde de obezite group of HIV infected and excess fat percentage over 9.21%. Cystatin-C decreased with GFRcys in the group of HIV infected and excess fat percentage under 9.21%.Conclusion: Higher correlation with cystatin-C and high body weight in HIV infected with excess fat percentage obese individuals suggests that inflammation due to HIV infection and excess fat mass together contribute to cystatin-C increasing levels. More studies are needed in large number of groups

Keywords

• HIV infection, GFR, obesity, fat mass

References

1. 1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377:13-27.
2. 2. Oğuz A, Temizhan A, Abaci A, et al. Obesity and abdominal obesity; an alarming challenge for cardio-metabolic risk in Turkish adults. Anadolu Kardiyol Derg 2008; 8: 401-6.
3. 3. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600.
4. 4. Satirapoj B, Supasyndh O, Mayteedol N, Punpanich D, Chaiprasert A, Nata N, et al. Obesity and its relation to chronic kidney disease: a populationbased, cross-sectional study of a Thai army population and relatives. Nephrology (Carlton) 2013;18:229-34.
5. 5. Muntner P, Winstan J, Uribarri J, Mann D, Fox CS.Overweight and obesity and elevated serum cystatin C levels in US adults.Am J Med. 2008 121(4):341348.doi:10.1016/j. amjmed.2008.01.003.
6. 6. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-19.
7. 7. Smith ER. “Cystatin C - More than a fltration marker?” Atherosclerosis 2013;230:173–5.
8. 8. Shi GP, Sukhova GK, Grubb A,Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999;104:1191–7.

9. 9. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991;285:213–9.
10. 10. Filler G, Bokenkamp A, Hofmann W, LeBricon T, Martinez-Bru C, Grubb A. Cystatin C As A Marker of GFR -History, Indications, and Future Research. Clinical Biochemistry. 2005; 8:1–8.
11. 11. Peralta CA, Shlipak MG, Judd S,Cushman M, McClellan M, Zakai NA et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albuminto-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011; 305:1545–52.
12. 12. Dragovic G , Srdic D , Musalhi KA , Soldatovic I , Kusic J , Jevtovic D ,et al. Higher Levels of Cystatin C in HIV/AIDS Patients with Metabolic Syndrome .Basic & Clinical Pharmacology & Toxicology 2018;122:396-401 Doi: 10.1111/bcpt.12919.
13. 13. Jones CY, Jones CA, Wilson IB, Knox TA, Levey AS, Spiegelman D, et al.Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study. Am J Kidney Dis. 2008 ;51(6):914-24. doi: 10.1053/j.ajkd.2008.01.027.
14. 14. Kotler D. Nutritional Alterations Associated with HIV Infection. JAIDS. 2000; 25:81–7.
15. 15. Massey D. Commentary: Clinical Diagnostic Use of Cystatin C. Journal of Clinical Laboratory Analysis. 2004; 18:55–60.
16. 16. De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS ONE 2013;8:e63623.
17. 17. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010 Jun 15;201(12):1788-95. doi: 10.1086/652749.
18. 18. Dolan SE, Hadigan C, Killilea, Sullivan MP, Hemphill L, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005;39:44-54.
19. 19. Lucas GM, Cozzi-Leori A, Wyatt CM, Post FA, Bormann AM, Crum- Cianflone NF et al; INSIGHT SMART Study Group. Glomerular filtration rate estimated using creatinine,cystatin C or both markers and the risk of clinical events in HIVinfected individuals. HIV Med. 2014;15(2):116-23. doi: 10.1111/hiv.12087.
20. 20. Naour N, Fellahi S, Renucci JF, Poitou C, Rouault C, Basdevant A, et al. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring). 2009;17(12): 2121-6.
21. 21. Cancello R, Henegar C, Viguerie N et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss.Diabetes 2005;54:2277-86.